Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer

Nagourney, Robert A.; Flam, Marshall S.; Link, John S.; Hager, Steven; Blitzer, Jonathan B.; Lyons, William S.; Sommers, B.; Evans, Steven S.

doi:10.3816/cbc.2008.n.052

Cited by 19 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Observed toxicities were similar to those seen in the previous study [94]. In a third smaller study on 13 patients, an RR of 53.3%, a median TTP of 4.5 months and a median OS of 28.8 months were observed [95]. More recently, Chan et al [96] evaluated this combination in 41 anthracycline- and taxane-resistant MBC patients and documented an RR of 39% (CR 2%, PR 37%).…”

Section: Experience With Combination Chemotherapysupporting

confidence: 70%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.

show abstract

Section: Experience With Combination Chemotherapysupporting

confidence: 70%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Two randomized controlled trials have demonstrated the efficacy of gemcitabine/taxane combinations as first-line and/or second-line treatment for metastatic breast cancer [9,10]. Many other studies have examined the efficacy and safety of gemcitabine in combination with paclitaxel, carboplatin, or cisplatin in patients with advanced metastatic breast cancer [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. However, most of these studies have involved small numbers of patients, and it is difficult to compare the results because of differences in the treatment regimens and the clinically diverse study populations.…”

Section: Introductionmentioning

confidence: 99%

Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial

Jiang

Kim

et al. 2011

Breast Cancer

View full text Add to dashboard Cite

show abstract

“…25,26 For example, gemcitabine is a deoxycytidine analog and is widely used in the treatment of solid tumors. [27][28][29] However, tumor resistance of gemcitabine often seriously limits its effect. 30 These drugs may interact with DNA in two ways: by acting as structural analogs of the precursors and intermediates for the synthetic pathway, and therefore interfering with the synthesis of purines and pyrimidines, or by acting as false bases in the assembly of the DNA double helix during replication and transcription.…”

Section: Antimetabolitesmentioning

confidence: 99%

“…10 Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a deoxycytidine analog with antitumor activity against a wide variety of solid tumors such as pancreatic, non-small-cell lung cancer (NSCLC), breast cancer, and ovarian cancer, alone or in combination with other chemotherapeutic agents. [27][28][29]96 Moreover, gemcitabine is indicated in several hematological disorders such as acute leukemia. 97 Furthermore, gemcitabine enhances the cytotoxicity of cisplatin by increasing the formation of cytotoxic platinum-DNA adducts and is also a potent radiosensitizer used in radiation therapy.…”

Section: Nucleoside Analogs and Gemcitabinementioning

confidence: 99%

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

Chen¹,

Zheng²,

Shi³

et al. 2018

IJN

View full text Add to dashboard Cite

Despite recent advances in targeted therapies and immunotherapies, chemotherapy using cytotoxic agents remains an indispensable modality in cancer treatment. Recently, there has been a growing emphasis in using nanomedicine in cancer chemotherapy, and several nanomedicines have already been used clinically to treat cancers. There is evidence that formulating small molecular cancer chemotherapeutic agents into nanomedicines significantly modifies their pharmacokinetics and often improves their efficacy. Importantly, cancer cells often develop resistance to chemotherapy, and formulating anticancer drugs into nanomedicines also helps overcome chemoresistance. In this review, we briefly describe the different classes of cancer chemotherapeutic agents, their mechanisms of action and resistance, and evidence of overcoming the resistance using nanomedicines. We then emphasize on gemcitabine and our experience in discovering the unique (stearoyl) gemcitabine solid lipid nanoparticles that are effective against tumor cells resistant to gemcitabine and elucidate the underlying mechanisms. It seems that lysosomes, which are an obstacle in the delivery of many drugs, are actually beneficial for our (stearoyl) gemcitabine solid lipid nanoparticles to overcome tumor cell resistance to gemcitabine.

show abstract

Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer

Cited by 19 publications

References 13 publications

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

Contact Info

Product

Resources

About